We develop biological therapeutics for neurodegenerative diseases
Currently, there is no cure for Alzheimer Disease (AD) and Fronto-Temporal-Dementia (FTD). The global market for dementia treatment will more than double in value from $4.9 billion in 2013 to reach an estimated $13.3 billion by 2023, according to research and consulting firm GlobalData. Most AD patients are late-onset patients, displaying symptoms of the disease at the age of 60 or older. As populations age, AD is clearly an enormous unmet clinical need, levying a hefty toll on patients, families and societies. At its core, AD is caused by progressive synaptic regression and neural death in the brains of AD patients caused by the accumulation of toxic neuropeptides, including Tau and beta-amyloid peptides. Despite scientific advances in the etiology of AD, progress in the development and approval of new treatments against AD remains minuscule.
In-depth analysis of the biological processes at the root of the disease suggest that successful therapy will likely address multiple pathogenic pathways to prevent both tau and amyloid peptide toxicity, encourage synaptogenesis, protect neurons from cell death, and support healthy neuronal metabolism.
AD is a complex disease with multiple pathogenic pathways, in the context of an aging brain. Multiple cellular mechanisms linking mitochondrial metabolism, vascular health, synaptogenesis and neural toxicity are at play in addition to amyloid peptides (E. D. Roberson and L. Mucke Science 314, 781–784; 2006).
ED11 is a peptide inhibitor of caspase-6, a unique member of the caspase family. Caspase-6 is cleaving targets in multiple pathogenic pathways, including tau, beta-amyloids, synaptic impairment, microtubule system malfunction, protein degradation and axonal degeneration. The safety and therapeutic potential of caspase-6 inhibition was demonstrated using genetic approaches in mouse models of Huntington disease (HD) and AD. We designed and recently patented ED11, a CNS penetrating peptide that inhibits caspase-6. ED11 is not a general apoptosis inhibitor and has an excellent safety profile.
Pre-clinical in-vivo experiments demonstrated that:
•ED11 has an excellent safety profile in human cells and in mice
•ED11 penetrates the mouse brain
•ED11 inhibits caspase-6 cleavage of tau and other proteins
•ED11 reveres HD phenotype in the BACHD mouse model
•ED11 improves cognitive functions in AD mouse model (3xTg-AD)
We are enhencing the potency and delivery of ED11 for clinical evaluation in AD and FTD patients. We anticipate the emergence of a clinical lead for neurodegenerative patients based on our ED11 peptide in the next 18 month. US Patent US20150259392A1
Dr. Daniel Offen, Tel Aviv University, Israel
Dr. Offen earned his PhD in Molecular Biology at Weizmann Institute of Science and did his post-doctoral studies at the Albert Einstein College of Medicine in N.Y. Dr. Offen heads the Neurology Laboratory at Tel Aviv University and is an Associate Professor in the Department of Human Genetics and Biochemistry. Dr. Offen enjoys an internationally recognized reputation in neuroscience research. He has published over 150 original scientific papers on neurodegenerative diseases and is co-inventor in over a dozen patents, including those on which Brainstorm Cell Therapeutics’ pioneering technology is based. Dr. Offen is a co-founder of BrainStorm, a biotechnology company developing autologous stem cell therapies for ALS and currently conducting a Phase II clinical trial at Hadassah Medical Center in Jerusalem.
Dr. Haim Aviv, Rehovot, Israel
Dr. Aviv was a professor at the Weitzman Institute of Science in Rehovot. He founded the first and largest biotech company in Israel, Bio-Technology General (BTG). He also founded Pharmos, a company that was dedicated to the commercialization of a new drug for CNS stroke developed in the Hebrew University. He is currently the CEO of Herbamed, developing and manufacturing nutritional health supplements.
Dr. Tzvi Aviv, Toronto, Canada
Dr. Aviv works at the interface of medical sciences and businesses to bring new technological innovations into the market. Prior to founding ApoMed he worked in the Hospital for Sick Children in Toronto, he collaborated with neurosurgeons to compile, integrate and analyse data derived from brain tumors patients. He had conducted drug screening and pre-clinical validation of promising drugs targeting medulloblastoma and glioblastoma brain tumors.
ED11 therapeutic value in Huntington Disease is published
Aharony, Israel, et al. "A Huntingtin based peptide inhibitor of Caspase-6 provides protection from mutant Huntingtin induced motor and behavioral deficits." Human molecular genetics (2015).
“Peptides for the treatment of neurodegenerative diseases”
WO 2014057484 A1
US 20150259392 A1
EP 2906583 A1
The analytic and communication abilities gained through medical research and discovery, combined with presentation and business analytic skills acquired during my recent MBA, will be at your service. I am equipped with an analytical mind, strategic thinking abilities, an entrepreneurial ‘can-do’ spirit, and the capability to build relations with multiple stakeholders.
Copyright @ All Rights Reserved